ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Income Statement
NASDAQ:ADAP - Nasdaq - US00653A1079 - ADR - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M | |||
| Cost Of Goods | 70.00K | N/A | N/A | N/A | N/A | |||
| Gross Profit | 177.96M | N/A | N/A | N/A | N/A | |||
| Operating Expenses | 230.37M | 190.97M | 188.81M | 168.40M | 137.36M | |||
| Research and Development | 149.06M | 126.51M | 127.73M | 111.09M | 91.57M | |||
| Selling, General, and Administrative Expenses | 81.31M | 64.46M | 61.09M | 57.31M | 45.80M | |||
| Operating Income | -52.41M | -130.69M | -161.67M | -162.25M | -133.41M | |||
| Interest Income/Expense | 3.25M | 5.96M | 1.54M | 1.10M | 2.40M | |||
| Other Income/Expense | -1.73M | -807.00K | -540.00K | 3.85M | 1.07M | |||
| Non Recurring Items | -16.35M | 13.00M | -2.30M | N/A | N/A | |||
| Income Before Taxes | -67.24M | -112.53M | -162.96M | -157.30M | -129.93M | |||
| Income Tax | 3.58M | 1.34M | 2.50M | 790.00K | 160.00K | |||
| Net Income | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M | |||
| EBITDA | -41.18M | -120.85M | -155.59M | -155.68M | -125.81M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.27 | -0.55 | -0.99 | -0.99 | -0.87 | |||
| Non GAAP EPS | -0.19 | -0.66 | -1.00 | -1.02 | -0.96 | |||
| Statistics | ||||||||
| Gross Profit Margin | 99.96% | N/A | N/A | N/A | N/A | |||
| Profit Margin | -39.78% | -188.90% | -609.43% | -2570.57% | -3285.10% | |||
| Operating Profit Margin | -29.44% | -216.80% | -595.47% | -2638.21% | -3368.94% | |||
All data in USD